Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: a secondary analysis of an open-label, randomised, controlled, phase 2 trial-Reference-Cited by-同舟云学术

Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: a secondary analysis of an open-label, randomised, controlled, phase 2 trial

Published:2023-01 Issue: Volume:55 Page:101764
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Zhu Xiaofei^ORCID,Liu Wenyu^ORCID,Cao Yangsen,Ju Xiaoping,Zhao Xianzhi,Jiang Lingong,Ye Yusheng,Zhang Huojun

Publisher

Elsevier BV

Subject

General Medicine

Reference26 articles.

1. Cancer statistics;Siegel;CA Cancer J Clin,2020

2. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial;Zhu;Lancet Oncol,2022

3. Failure patterns and outcomes of dose escalation of stereotactic body radiotherapy for locally advanced pancreatic cancer: a multicenter cohort study;Zhu;Ther Adv Med Oncol,2020

4. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation;Krishnan;Int J Radiat Oncol Biol Phys,2016

5. Personalized designs of adjuvant radiotherapy for pancreatic cancer based on molecular profiles;Zhu;Cancer Sci,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma;World Journal of Clinical Oncology;2024-07-24

2. Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery;Journal of Clinical Medicine;2024-04-30

3. Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept;Journal of Experimental & Clinical Cancer Research;2024-01-02

4. Local ablative therapies and the effect on antitumor immune responses in pancreatic cancer – A review;Heliyon;2024-01

5. Overcoming the limitations of immunotherapy in pancreatic ductal adenocarcinoma: Combining radiotherapy and metabolic targeting therapy;Journal of Cancer;2024